EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FSCN1 as a new druggable target in adrenocortical carcinoma

Carmen Ruggiero, Mariangela Tamburello, Elisa Rossini, Silvia Zini, Nelly Durand, Giulia Cantini, Francesca Cioppi, Constanze Hantel, Katja Kiseljak-Vassiliades, Margaret E Wierman, Laura-Sophie Landwehr, Isabel Weigand und 8 weitere

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Carmen Ruggiero und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Pharmacologie Moléculaire et Cellulaire CNRS UMR 7275, 06560, Valbonne, France. Hauptthemen laut MEDLINE: Adrenal Cortex Neoplasms, Adrenocortical Carcinoma. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Agence Nationale de la Recherche, Fondation ARC pour la Recherche sur le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a high risk of relapse and metastatic spread. The actin‐bundling protein fascin (FSCN1) is overexpressed in aggressive ACC and represents a reliable prognostic indicator. FSCN1 has been shown to synergize with VAV2, a guanine nucleotide exchange factor for the Rho/Rac GTPase family, to enhance the invasion properties of ACC cancer cells. Based on those results, we investigated the effects of FSCN1 inactivation by CRISPR/Cas9 or pharmacological blockade on the invasive properties of ACC cells, both in vitro and in an in vivo metastatic ACC zebrafish model. Here, we showed that FSCN1 is a transcriptional target for β‐catenin in H295R ACC cells and that its inactivation resulted in defects in cell attachment and proliferation. FSCN1 knock‐out modulated the expression of genes involved in cytoskeleton dynamics and cell adhesion. When Steroidogenic Factor‐1 (SF‐1) dosage was upregulated in H295R cells, activating their invasive capacities, FSCN1 knock‐out reduced the number of filopodia, lamellipodia/ruffles and focal adhesions, while decreasing cell invasion in Matrigel. Similar effects were produced by the FSCN1 inhibitor G2‐044, which also diminished the invasion of other ACC cell lines expressing lower levels of FSCN1 than H295R. In the zebrafish model, metastases formation was significantly reduced in FSCN1 knock‐out cells and G2‐044 significantly reduced the number of metastases formed by ACC cells. Our results indicate that FSCN1 is a new druggable target for ACC and provide the rationale for future clinical trials with FSCN1 inhibitors in patients with ACC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticNeoplasm Recurrence, LocalZebrafishCarrier ProteinsMicrofilament ProteinsZebrafish Proteins

Stichwörter der Autor:innen

adrenocortical carcinomacytoskeletonendocrine cancer

Substanzen

fascinCarrier ProteinsMicrofilament ProteinsFSCN1 protein, humanfscn1a protein, zebrafishZebrafish Proteins

Autor:innen und Institutionen

  • Institut de Pharmacologie Moléculaire et Cellulaire CNRS UMR 7275, 06560, Valbonne, France.
  • Université Côte d'Azur, 06560, Valbonne, France.
  • Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, 25124, Brescia, Italy.
  • Endocrinology Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134, Florence, Italy.
  • Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50134, Florence, Italy.
  • Department of Experimental and Clinical Medicine, University of Florence, 50134, Florence, Italy.

ORCID-Profile: Michaela Luconi, Enzo Lalli

Förderung

  • NCI NIH HHS
  • Agence Nationale de la Recherche
  • Fondation ARC pour la Recherche sur le Cancer

Zitieren

APA

Ruggiero, C., Tamburello, M., Rossini, E., Zini, S., Durand, N., Cantini, G., Cioppi, F., Hantel, C., Kiseljak-Vassiliades, K., Wierman, M. E., Landwehr, L. S., Weigand, I., Kurlbaum, M., Zizioli, D., Turtoi, A., Yang, S., Berruti, A., Luconi, M., Sigala, S., & Lalli, E. (2023). FSCN1 as a new druggable target in adrenocortical carcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.34526

Vancouver

Ruggiero C, Tamburello M, Rossini E, Zini S, Durand N, Cantini G, et al. FSCN1 as a new druggable target in adrenocortical carcinoma. International Journal of Cancer. 2023. doi:10.1002/ijc.34526

BibTeX
@article{Ruggiero2023,
  author = {Ruggiero, Carmen and Tamburello, Mariangela and Rossini, Elisa and Zini, Silvia and Durand, Nelly and Cantini, Giulia and Cioppi, Francesca and Hantel, Constanze and Kiseljak-Vassiliades, Katja and Wierman, Margaret E and Landwehr, Laura-Sophie and Weigand, Isabel and Kurlbaum, Max and Zizioli, Daniela and Turtoi, Andrei and Yang, Shengyu and Berruti, Alfredo and Luconi, Michaela and Sigala, Sandra and Lalli, Enzo},
  title = {FSCN1 as a new druggable target in adrenocortical carcinoma},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34526}
}
Kostenlos starten →